The Event. Five days ago I wrote that the $150M private placement at $11.38 “looks like” a marketed deal without insider participation, and that the absence of Catalyst4 from the announcement was the tell. Today’s Schedule 13D/A (Amendment No. 2, filed 08/18, event date 08/14) says I read that wrong. Catalyst4 bought 4,400,000 shares of voting common plus pre-funded warrants for 2,928,686 more — $83,400,153.82, all of it from working capital, no borrowed funds.
The Reaction. Almost nothing. MPLT closed at $11.82 today against $11.58 on August 13 — +2.1% across the whole stretch. The market has now seen the negative-symptom miss, the raise, and the insider anchor, and has priced the composite at roughly nothing.
The Reality. More than 55% of the $150M PIPE was bought by the controlling holder. That is not the structure I described on August 13, and it changes the “what would reverse it” condition I set on August 4.
The size, and the share of the deal. Catalyst4 took 4,400,000 common plus 2,928,686 pre-funded warrant shares — 7,328,686 of the 13,181,055 total, or about 55.6% of the offering, for $83.4M. The implication: the “new and existing institutional investors” framing in the August 13 press release was doing heavy lifting. The largest single buyer of MapLight’s dilution was MapLight’s own control vehicle.
The pre-funded warrant tell, revised. I wrote on August 13 that roughly 30% of the deal going out as pre-funded warrants was “the signature of one or more large dedicated funds building a real position — the most encouraging thing in the financing documents.” Wrong buyer. Catalyst4’s 2,928,686 warrants account for the substantial majority of the 3,983,168 total, and they exist for a mechanical reason: Catalyst4 is prohibited from exercising above 49.99% of voting common. Why it matters: the constructive read on outside demand shrinks accordingly. Third-party institutional participation in this raise was roughly $67M, not $150M.
The stake, post-close. 27,536,011 shares / 49.9%, based on 52,848,208 voting shares outstanding as of August 14 plus the 2,229,322 warrant shares exercisable within 60 days. A further 699,364 warrant shares are stranded by the 49.99% cap. The implication: on August 13 I estimated the raise would dilute Catalyst4 from 47.9% down to roughly 39–40% on a non-participating basis. Instead it went up, to the ceiling. The control block did not thin — it thickened to the maximum the instrument allows.
The running cost basis. Catalyst4 bought 1,209,225 shares around $12.65 in late July, then 7,328,686 at $11.38 in August. Roughly $98.7M of working capital deployed in under three weeks at an average near $11.56. Why it matters: my deep dive priced the Catalyst4/Stellaromics related-party structure as a governance discount. That same entity has now put nearly $100M of cash behind the equity at prices between 65% and 69% below the July 24 close of $36.56.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.